Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Oral lichen planus (OLP) is a chronic disease characterized by periods of remission and
relapse. Therapeutic objectives for OLP should be to quickly reduce disease symptoms by
targeting pathophysiological pathways, and to provide long-term management by reducing
recurrences. Pimecrolimus is a novel topical selective inflammatory cytokine release
inhibitor; considering its mechanism of action it is reasonable to theorize that pimecrolimus
may effectively treat OLP without the potential side effects that are associated with
corticosteroids.